Methods for detecting and developing protein-protein or protein-RNA interactions
Potent and selective recognition of disease-relevant macromolecules - such as proteins and RNA - is the molecular basis of most pharmaceuticals . Historically, small (< 500 Da) molecules have filled this role. However, the overwhelming majority (~85%) of the proteome - and emerging therapeutic targets such as RNA - present a serious challenge to small molecule-dependent recognition. An alternative approach to potent and selective recognition and regulation of disease-relevant proteins and RNA is to use synthetic proteins. In contrast to small molecules, the size, relatively high folding energies ...
(For more, see "View full record.")